Press Releases

Print

OUSA celebrates 10 years of LDR prostate brachytherapy and the treatment of its 1,000th patient with IsoSeed®

Seneffe, Belgium, March 15, 2018. OUSA - Onkologický ústav sv. Alžbety (Oncological Institute of St. Elizabeth) in Bratislava, Slovakia, is celebrating 10 years of LDR prostate brachytherapy and the treatment of its 1,000th patient with IsoSeed®.

In celebration of its achievements in LDR Prostate Brachytherapy, today, OUSA is hosting a conference entitled "Brachytherapy in Prostate Cancer", together with the Slovak Society of Radiological Oncology. The conference topics include new trends in prostate cancer diagnosis, imaging and disease management.

During the conference, Eckert & Ziegler BEBIG will formally congratulate OUSA on its valuable efforts in brachytherapy and thank it for its continuous trust in the company's seed brachytherapy products. With the treatment of its 1,000th patient with IsoSeed®, OUSA is one of Eckert & Ziegler BEBIG's highest volume customers. "Since 2007, we have received a constantly outstanding service and are looking forward to continuing our relationship with Eckert & Ziegler BEBIG", says Dr. Pavol Lukacko, Radiation Oncologist at OUSA.

About LDR Prostate Brachytherapy
In this form of treatment, small radioactive iodine-125 sources, so called seeds, are placed inside the prostate. By placing the seeds evenly throughout the organ, the prostate is covered with the designated dose required to destroy the cancerous cells. Since irradiation is mainly localized around the radioactive source, neighboring tissues are spared unnecessary damage.

LDR or permanent brachytherapy is the most conservative treatment method for early-stage prostate cancer. Its international popularity has increased continuously since the early 1990s and it is now generally accepted as a state-of-the art therapy. Prostate seed implantation is an effective and well-tolerated method for curing prostate cancer. The cure rates are comparable to the ones of external beam radiation therapy and prostatectomy for early-stage prostate cancer.

About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the healthcare industry. Its core business is the production and distribution of medical products for the treat­ment of cancer, using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 145 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:
Annica Witt
Marketing Communication Manager
marketing@bebig.com
www.bebig.com

Back